Literature DB >> 3160707

Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation.

R L Silverstein, R L Nachman, L L Leung, P C Harpel.   

Abstract

Ternary complex formation of tissue plasminogen activator (TPA) and plasminogen (Plg) with thrombospondin (TSP) or histidine-rich glycoprotein (HRGP) has been demonstrated using an enzyme-linked immunosorbent assay, an affinity bead assay, and a rocket immunoelectrophoresis assay. The formation of these complexes was specific, concentration dependent, saturable, lysine binding site-dependent, and inhibitable by fluid phase plasminogen. Apparent Kd values were approximately 12-36 nM for the interaction of TPA with TSP-Plg complexes and 15-31 nM with HRGP-Plg complexes. At saturation the relative molar stoichiometry of Plg:TPA was 3:1 within the TSP-containing complexes and 1:1 within HRGP-containing complexes. The activation of Plg to plasmin by TPA on TSP- and HRGP-coated surfaces was studied using a synthetic fluorometric plasmin substrate (D-Val-Leu-Lys-7-amino-4-trifluoromethyl coumarin). Kinetic analysis demonstrated a marked increase in the affinity of TPA for plasminogen in the presence of surface-associated TSP or HRGP. Compared to fluid phase activation or activation on fibronectin- or Factor VIII-related antigen-coated surfaces there was a 35-fold increase in efficiency of plasmin generation. A substantial amount (up to 71%) of the plasmin formed remained surface-associated and was found to be protected from inhibition by alpha 2-plasmin inhibitor. Greater than 200-fold increase in inhibitor concentration was required to effect 50% inhibition. Complex formation of locally released tissue plasminogen activator with Plg immobilized on TSP or HRGP surfaces may thus play an important role in effecting proteolytic events in nonfibrin-containing microenvironments.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160707

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Thrombospondin as a mediator of cancer cell adhesion in metastasis.

Authors:  D A Walz
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Binding of human plasminogen to basement-membrane (type IV) collagen.

Authors:  M S Stack; T L Moser; S V Pizzo
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors:  J M Edelberg; M Weissler; S V Pizzo
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

4.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 5.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

Review 6.  The haemostatic function of the vascular endothelial cell.

Authors:  H A Bull; S J Machin
Journal:  Blut       Date:  1987-08

7.  Binding of tissue plasminogen activator to cultured human endothelial cells.

Authors:  K A Hajjar; N M Hamel; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

8.  Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.

Authors:  R Simantov; M Febbraio; R Crombie; A S Asch; R L Nachman; R L Silverstein
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

9.  Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion.

Authors:  R L Silverstein; A S Asch; R L Nachman
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

10.  Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion.

Authors:  R L Silverstein; R L Nachman
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.